Galvanize Therapeutics
Redwood City, US · Founded 2015 · Delaware corporation · 173 employees on LinkedIn · 13 known investors
Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms. Its products serve clinical fields such as interventional pulmonology and thoracic surgery.
Founders & leadership
DG
Doug GodshallExecutive
SA
Steve AnheierExecutive
Board
JW
Jonathan WaldstreicherBoard directorPartner at Apple Tree Venture Management Llc
AP
SH
Seth HarrisonBoard director
ZS
Zack ScottBoard director
DL
David LewisBoard director
Investors · 13
Norwest Venture PartnersMenlo Park · $10M – $30M
Ally Bridge Groupreported · 2 sourcesNew York
ATPreportedAustin
Fidelity Investmentsreported · 2 sourcesBoston
Gilmartin Capital LLCreported · 2 sourcesLarkspur
Janus Henderson InvestorsreportedLondon
Perceptive Xontogeny Venturereported · 2 sourcesNew York
Sofinnova Partnersreported · 3 sourcesParis · $540K – $27Mvia Antoine Papiernik Papiernik · board
T. Rowe PricereportedBaltimore
Also in the syndicate · 4
Apple Tree PartnersElevage Medical TechnologiesIntuitive SurgicalLongaeva
Reported raises · per SEC filings
Form D private placements$144.6M disclosed across 4 rounds · 2015–2025
▶$96.1MraisedSep 2025 · 28 investors · BiotechnologyRule 506(b)
▶$96.1MraisedSep 2025 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Doug GodshallExecutive Officer, Director
- Jonathan WaldstreicherExecutive Officer
- Antoine PapiernikDirector
- David LewisDirector
- Steve AnheierExecutive Officer
- Seth HarrisonDirector
- Zack ScottDirector
- Offering amount
- $141.1M
- Amount sold
- $96.1M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedMar 2022 · 1 investors · BiotechnologyRule 506(b)
▶$4MraisedMar 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan WaldstreicherExecutive Officer, Director
- Seth HarrisonDirector
- Doug GodshallDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedMar 2022 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedMar 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Seth HarrisonDirector
- Doug GodshallDirector
- Jonathan WaldstreicherExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$42.5MraisedNov 2019 · 1 investors · BiotechnologyRule 506(b)
▶$42.5MraisedNov 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan WaldstreicherExecutive Officer, Director
- Seth HarrisonDirector
- Offering amount
- $43M
- Amount sold
- $42.5M
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Galvanize11 shared keywordsGalvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations. It focuses on onboarding, reskilling, upskilling, and assessments aimed at improving software delivery and business outcomes.
Companies competing with Galvanize Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Galvanize Therapeutics do?
- Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms. Its products serve clinical fields such as interventional pulmonology and thoracic surgery.
- Who are Galvanize Therapeutics's investors?
- Galvanize Therapeutics's investors include Norwest Venture Partners, Ally Bridge Group, ATP, Fidelity Investments, Gilmartin Capital LLC, Janus Henderson Investors, Perceptive Xontogeny Venture, Sofinnova Partners and 1 more.
- How much funding has Galvanize Therapeutics raised?
- Galvanize Therapeutics has disclosed $144.6M raised across 4 rounds.
- Where is Galvanize Therapeutics headquartered?
- Galvanize Therapeutics is headquartered in Redwood City, US.